Skip to main content

Table 1 Characteristics of subjects with total high-grade salivary gland cancers (n = 124) and resectable high-grade salivary gland cancers (n = 103)

From: Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1–2 N0 high-grade salivary gland cancer

Characteristics No. %
Total high-grade salivary gland cancers (n = 124)
 Age [years; median (range)] 61 (31–89)  
 Gender (Male/Female) 95/29 76.6/23.4
 Tumor site
  Parotid gland 84 67.7
  Submandibular gland 38 30.6
  Sublingual gland and minor salivary gland 2 1.6
 T classification
  T1 20 16.1
  T2 44 35.5
  T3 23 18.5
  T4 37 29.8
 N classification
  N0 63 50.8
  N1 10 8.1
  N2–3 51 41.1
 M classification
  M0 109 87.9
  M1 15 12.1
 AJCC TNM stage
  I 14 11.3
  II 24 19.4
  III 16 12.9
  IV 70 56.5
 Pathological diagnosis
  Salivary duct carcinoma 74 59.7
  Squamous cell carcinoma, primary* 13 10.5
  Adenoid cystic carcinoma, solid type 12 9.7
  Mucoepidermoid carcinoma, high-grade 9 7.3
  Adenocarcinoma, high-grade 6 4.8
  Atypical high-grade carcinoma 3 2.4
  Carcino-sarcoma, high-grade 4 3.2
  Poorly differentiated carcinoma 3 2.4
 Treatment modalities
  Surgery alone 13 10.5
  Surgery + adjuvant radiation 62 50.0
  Surgery + adjuvant radiation + chemotherapy 28 22.6
  Initial non-surgical local treatment (radiation or chemoradiation) 3 2.4
  Chemotherapy or palliative treatment 18 14.5
 Clinical outcomes
  Disease-specific death 39 31.5
  Event-free follow-up period [months; median (range)] 109 [2–188]  
  All-cause death 44 35.5
Resectable high-grade salivary gland caners (n = 103)
 Surgery for primary tumor
  R0 resection (cancer cells absent at the resection margin) 97 94.2
  R1 resection (cancer cells present at the resection margin) 6 5.8
 Neck dissection
  No 31 30.1
  Selective neck lymph node dissection 30 29.1
  Comprehensive neck lymph node dissection 42 40.8
 Pathological risk factors
  Perineural invasion (Y/N) 13/90 12.6/87.4
  Lymphovascular invasion (Y/N) 16/87 15.5/84.5
  Extra-parenchymal (Extra-glandular) extension of tumor (Y/N) 45/58 43.7/56.3
  Extra-capsular spread of lymph node metastasis (Y/N) 26/77 25.2/74.8
 Clinical outcomes
  Recurrence 40 38.8
  Recurrence-free period [months; median (range)] 109 [2–188]  
  Disease-specific death 27 26.2
  Event-free follow-up period [months; median (range)] 123 [2–188]  
  1. Abbreviation:
  2. AJCC TNM stage: 7th edition of the American Joint Committee on Cancer staging manuals (2010)
  3. Y: presence, N: absence
  4. *No evidence of squamous cell carcinomas in other sites, in imaging studies and clinical follow-ups.